Zeus shield T cell therapy - Wellington Zhaotai Therapies
Alternative Names: Zeus Shield T - Wellington Zhaotai TherapiesLatest Information Update: 30 Apr 2025
At a glance
- Originator Wellington Zhaotai Therapies
- Class Antineoplastics; Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase I Gastric cancer; Liver cancer; Pancreatic cancer
Most Recent Events
- 29 Apr 2025 Zeus shield T cell therapy is available for licensing as of 29 Apr 2025. https://www.wellingtonzhaotai.com/business-development (Wellington Zhaotai Therapies, April 2025)
- 26 Mar 2025 Phase I trials in Pancreatic cancer (Parenteral) (Wellington Zhaotai Therapies pipeline, March 2025)
- 26 Mar 2025 Phase-I clinical trials in Gastric cancer (Parenteral) (Wellington Zhaotai Therapies pipeline, March 2025)